Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 25 09:54AM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-2.93 Insider Own14.22% Shs Outstand35.69M Perf Week-10.27%
Market Cap51.24M Forward P/E- EPS next Y-0.20 Insider Trans-0.47% Shs Float30.61M Perf Month-30.64%
Income-51.85M PEG- EPS next Q-0.27 Inst Own13.61% Short Float12.35% Perf Quarter-16.04%
Sales0.10M P/S512.40 EPS this Y62.57% Inst Trans1.32% Short Ratio7.97 Perf Half Y-29.62%
Book/sh-0.47 P/B- EPS next Y83.14% ROA-555.46% Short Interest3.78M Perf Year-49.27%
Cash/sh0.14 P/C10.39 EPS next 5Y- ROE- 52W Range1.30 - 3.62 Perf YTD-37.31%
Dividend Est.- P/FCF- EPS past 5Y26.32% ROI- 52W High-60.34% Beta0.99
Dividend TTM- Quick Ratio0.29 Sales past 5Y-47.67% Gross Margin- 52W Low10.44% ATR (14)0.11
Dividend Ex-Date- Current Ratio0.29 EPS Y/Y TTM57.14% Oper. Margin-50629.13% RSI (14)22.68 Volatility8.93% 6.24%
Employees23 Debt/Eq- Sales Y/Y TTM-46.35% Profit Margin-50336.89% Recom1.00 Target Price17.25
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q65.70% Payout- Rel Volume0.58 Prev Close1.44
Sales Surprise-80.00% EPS Surprise-63.48% Sales Q/Q-91.89% EarningsMar 22 BMO Avg Volume474.12K Price1.44
SMA20-18.32% SMA50-25.08% SMA200-31.69% Trades Volume30,040 Change-0.30%
Date Action Analyst Rating Change Price Target Change
Jul-14-22Resumed B. Riley Securities Buy $7
Jun-09-21Initiated B. Riley Securities Buy $18
Jan-20-21Initiated Cantor Fitzgerald Overweight $16
May-29-19Initiated Lake Street Buy
Dec-08-17Initiated H.C. Wainwright Buy $11
Mar-28-24 04:05PM
Mar-22-24 02:52PM
Mar-18-24 08:00AM
Jan-29-24 08:00AM
08:15AM Loading…
Jan-11-24 08:15AM
Dec-18-23 07:31AM
Dec-11-23 12:26PM
Dec-05-23 08:30AM
Nov-13-23 05:00PM
Oct-18-23 08:30AM
Oct-02-23 12:53PM
Sep-21-23 08:30AM
08:30AM Loading…
Sep-06-23 08:30AM
Aug-14-23 04:15PM
Jul-31-23 08:00AM
Jul-27-23 07:00AM
Jun-28-23 08:00AM
May-23-23 08:30AM
May-21-23 10:03AM
May-15-23 04:15PM
Apr-02-23 08:37AM
Mar-31-23 08:00AM
Mar-30-23 08:00PM
Mar-02-23 07:00AM
08:00AM Loading…
Feb-21-23 08:00AM
Jan-17-23 08:30AM
Jan-04-23 08:00AM
Jan-01-23 09:36AM
Dec-15-22 08:00AM
Dec-05-22 04:30PM
Nov-08-22 04:30PM
Sep-22-22 08:30AM
Sep-08-22 08:15AM
Aug-12-22 08:00AM
Jun-30-22 10:19AM
Jun-16-22 09:29AM
Jun-06-22 04:30PM
May-19-22 08:30AM
May-13-22 08:30AM
May-12-22 04:30PM
Apr-28-22 08:00AM
Apr-04-22 08:15AM
Apr-01-22 08:30AM
Mar-31-22 07:10PM
Mar-28-22 07:30AM
Mar-10-22 10:55AM
Jan-26-22 10:00AM
Jan-25-22 04:30PM
Dec-08-21 08:30AM
Nov-04-21 04:30PM
Sep-22-21 08:30AM
Sep-09-21 08:30AM
Aug-06-21 02:13AM
Aug-05-21 04:30PM
Jul-08-21 08:30AM
Jun-09-21 06:01PM
Jun-03-21 08:00AM
May-12-21 08:00AM
May-08-21 04:23AM
May-06-21 04:15PM
Mar-09-21 04:30PM
Mar-04-21 08:00AM
Mar-01-21 08:30AM
Feb-11-21 11:16AM
Jan-06-21 08:30AM
Dec-09-20 12:15AM
Nov-27-20 01:06PM
Nov-09-20 08:00AM
Nov-04-20 04:25PM
Nov-02-20 07:00AM
Oct-25-20 09:08AM
Sep-19-20 10:01AM
Sep-17-20 05:27PM
Sep-14-20 07:19AM
Sep-10-20 08:00AM
Sep-08-20 10:02AM
Aug-17-20 08:00AM
Aug-05-20 04:30PM
Jul-27-20 07:30AM
Jul-21-20 06:59AM
Jul-16-20 03:27PM
May-27-20 01:42PM
May-22-20 08:30AM
May-20-20 08:33AM
May-09-20 08:41AM
Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. Its product portfolio includes CK-301, CK-101, CK-103, CK-302, and Anti-CAIX. The company was founded on November 10, 2014 and is headquartered in Waltham, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Oliviero James F IIICEO, President and DirectorFeb 28 '24Sale2.065,89412,142350,836Mar 01 08:31 PM
GRAY WILLIAM GARRETTChief Financial OfficerFeb 28 '24Sale2.072,0354,212145,224Mar 01 08:30 PM
Oliviero James F IIICEO, President and DirectorFeb 01 '24Sale2.0111,90023,919369,680Feb 02 08:10 PM
GRAY WILLIAM GARRETTChief Financial OfficerFeb 01 '24Sale1.954,1158,024147,259Feb 02 08:15 PM